BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16757435)

  • 21. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
    Grigg A; Kimber R; Szer J
    Leukemia; 2003 Sep; 17(9):1916-7; author reply 1918. PubMed ID: 12970801
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
    Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
    Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
    Dunkley S; Gibson J; Iland H; Li C; Joshua D
    Leuk Lymphoma; 1999 Nov; 35(5-6):623-6. PubMed ID: 10609802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
    Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
    Tavernier E; Thomas X
    Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
    Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
    Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT.
    Nasilowska-Adamska B; Majewski M; Seferynska I; Szczepinski A; Tomaszewska A; Prochorec-Sobieszek M; Guz K; Torbicki A; Warzocha K; Marianska B
    Ann Transplant; 2007; 12(3):33-8. PubMed ID: 18290568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
    N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
    Gutiérrez NC; García JL; Chillón C; Muntión S; González M; Hernández JM
    Haematologica; 1999 Jan; 84(1):88-90. PubMed ID: 10091399
    [No Abstract]   [Full Text] [Related]  

  • 38. A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia.
    García-Casado Z; Cervera J; Valencia A; Pajuelo JC; Mena-Duran AV; Barragán E; Bolufer P; Sanz MA
    Cancer Genet Cytogenet; 2006 Jul; 168(1):73-6. PubMed ID: 16772124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.